Statement of Changes in Beneficial Ownership (4)
February 09 2022 - 3:37PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Mai Xiaoying |
2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp
[
TWST
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O TWIST BIOSCIENCE CORPORATION, 455 MISSION BAY BOULEVARD SOUTH |
3. Date of Earliest Transaction
(MM/DD/YYYY)
2/7/2022 |
(Street)
SAN FRANCISCO, CA 94158
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 2/7/2022 | | A | | 13539 (1) | A | $0 | 13539 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Director Stock Option (right to buy) | $60.33 | 2/7/2022 | | A | | 10588 | | (1) | 7/22/2029 | Common Stock | 10588 | $0 | 10588 | D | |
Director Stock Option (right to buy) | $60.33 | 2/7/2022 | | A | | 11297 | | (1) | 2/3/2030 | Common Stock | 11297 | $0 | 11297 | D | |
Director Stock Option (right to buy) | $189.96 | 2/7/2022 | | A | | 973 | | (1) | 2/2/2031 | Common Stock | 973 | $0 | 973 | D | |
Explanation of Responses: |
(1) | Each equity is fully vested at the time of grant, but represent equity awards for prior annual meetings in 2019, 2020 and 2021 that the Company was not able to grant. If the grants had been made at the time of the prior annual meetings, each grant would have vested upon the earlier of (1) the 1 year anniversary of the date of grant or (2) the next annual meeting. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Mai Xiaoying C/O TWIST BIOSCIENCE CORPORATION 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO, CA 94158 | X |
|
|
|
Signatures
|
/s/ William Solis, as Attorney-in-Fact for Xiaoying Mai | | 2/9/2022 |
**Signature of Reporting Person | Date |
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024